Pharmaceutical companies have spent something like $50 billion on developing Alzheimer's drugs with, well, the most furtive of straw-grasping to show for it. It's probably the most expensive single disease target (especially as things like cancer are families of diseases)... the failure to have good results isn't for lack of money, and merely throwing more money at it is unlikely to actually make progress towards meaningful treatments.